Skip to main content
Top
Published in: International Ophthalmology 1/2021

01-01-2021 | Chloroquin | Original Paper

Is optical coherence tomography angiography a useful tool in the screening of hydroxychloroquine retinopathy?

Authors: Hatice Nur Tarakcioglu, Abdullah Ozkaya, Ulviye Yigit

Published in: International Ophthalmology | Issue 1/2021

Login to get access

Abstract

Purpose

To detect the early changes in retinal vasculature via optical coherence tomography angiography (OCTA) by comparing the quantitative OCTA parameters in the group of patients who were using hydroxychloroquine (HCQ) or not.

Methods

This was a cross-sectional, comparative, and observational study. The patients who were newly or previously prescribed HCQ for an autoimmune disease were included. OCTA imaging was performed via OCT RT XR Avanti with AngioVue software (Optivue Inc, Freemont, CA). The study group had two groups: a control group (patients newly diagnosed and who were not taking any medication) and a treatment group (patients who were receiving HCQ treatment). The main outcome measure was OCTA parameters.

Results

A total of 102 eyes of 102 patients were included. There were 70 patients in the treatment group and 32 patients in the control group. All of the vascular density values were similar between the control and treatment groups (p > 0.05 for all). However, the superficial whole thickness, superficial parafoveal thickness, superficial perifoveal thickness, deep whole thickness, deep parafoveal thickness, and deep perifoveal thickness were thinner in the treatment group than the control group (p < 0.05 for all).

Conclusion

Vascular density parameters did not differ between the control and treatment groups. However, the retinal thickness values were lower in the treatment group.
Literature
1.
go back to reference Monzavi SM, Alirezaei A, Shariati-Sarabi Z, Afshari JT et al (2018) Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. Inflammopharmacol 26:1175–1182CrossRef Monzavi SM, Alirezaei A, Shariati-Sarabi Z, Afshari JT et al (2018) Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers. Inflammopharmacol 26:1175–1182CrossRef
2.
go back to reference Hanaoka H, Lida H, Kiyokawa T, Takakuwa Y, Kawahata K (2019) Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Clin Rheumatol 38:2785–2791CrossRef Hanaoka H, Lida H, Kiyokawa T, Takakuwa Y, Kawahata K (2019) Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Clin Rheumatol 38:2785–2791CrossRef
3.
go back to reference Yusuf IH, Sharma S, Luqmani R, Downes SM (2017) Hydroxychloroquine retinopathy. Eye (Lond) 31:828–845CrossRef Yusuf IH, Sharma S, Luqmani R, Downes SM (2017) Hydroxychloroquine retinopathy. Eye (Lond) 31:828–845CrossRef
5.
go back to reference Bernstein HN (1991) Ocular safety of hydroxychloroquine. Ann Ophthalmol 23:292–296PubMed Bernstein HN (1991) Ocular safety of hydroxychloroquine. Ann Ophthalmol 23:292–296PubMed
6.
go back to reference Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460CrossRef Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460CrossRef
7.
go back to reference Wetterholm DH, Winter FC (1964) Histopathology of chloroquine retinal toxicity. Arch Ophthalmol 71:82–87CrossRef Wetterholm DH, Winter FC (1964) Histopathology of chloroquine retinal toxicity. Arch Ophthalmol 71:82–87CrossRef
8.
go back to reference Korthagen NM, Bastiaans J, van Meurs JC, van Bilsen K, van Hagen PM, Dik WA (2015) Chloroquine and hydroxychloroquine increase retinal pigment epithelial layer permeability. J Biochem Mol Toxicol 29:299–304CrossRef Korthagen NM, Bastiaans J, van Meurs JC, van Bilsen K, van Hagen PM, Dik WA (2015) Chloroquine and hydroxychloroquine increase retinal pigment epithelial layer permeability. J Biochem Mol Toxicol 29:299–304CrossRef
9.
go back to reference Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118:415–422CrossRef Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118:415–422CrossRef
10.
go back to reference Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394CrossRef Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394CrossRef
11.
go back to reference Kellner U, Renner AB, Tillack H (2006) Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 47:3531–3538CrossRef Kellner U, Renner AB, Tillack H (2006) Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 47:3531–3538CrossRef
12.
go back to reference Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG (2015) Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 122:1239–1251CrossRef Tsang AC, Ahmadi Pirshahid S, Virgili G, Gottlieb CC, Hamilton J, Coupland SG (2015) Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 122:1239–1251CrossRef
13.
go back to reference Bulut M, Akıdan M, Gözkaya O, Erol MK, Cengiz A, Çay HF (2018) Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations. Graefes Arch Clin Exp Ophthalmol 256:2075–2081CrossRef Bulut M, Akıdan M, Gözkaya O, Erol MK, Cengiz A, Çay HF (2018) Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations. Graefes Arch Clin Exp Ophthalmol 256:2075–2081CrossRef
14.
go back to reference Goker YS, Ucgul Atılgan C, Tekin K, Kızıltoprak H et al (2019) The validity of optical coherence tomography angiography as a screening test for the early detection of retinal changes in patients with hydroxychloroquine therapy. Curr Eye Res 44:311–315CrossRef Goker YS, Ucgul Atılgan C, Tekin K, Kızıltoprak H et al (2019) The validity of optical coherence tomography angiography as a screening test for the early detection of retinal changes in patients with hydroxychloroquine therapy. Curr Eye Res 44:311–315CrossRef
17.
go back to reference Sarwar S, Hassan M, Soliman MK, Halim MS et al (2018) Diurnal variation of choriocapillaris vessel flow density in normal subjects measured using optical coherence tomography angiography. Int J Retina Vitreous 4:37CrossRef Sarwar S, Hassan M, Soliman MK, Halim MS et al (2018) Diurnal variation of choriocapillaris vessel flow density in normal subjects measured using optical coherence tomography angiography. Int J Retina Vitreous 4:37CrossRef
18.
go back to reference Ulviye Y, Betul T, Nur TH, Selda C (2013) Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine. Indian J Ophthalmol 61:168–171CrossRef Ulviye Y, Betul T, Nur TH, Selda C (2013) Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine. Indian J Ophthalmol 61:168–171CrossRef
19.
go back to reference Kan E, Yakar K, Demirag MD, Gok M (2018) Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine. Int Ophthalmol 38:1635–1640CrossRef Kan E, Yakar K, Demirag MD, Gok M (2018) Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine. Int Ophthalmol 38:1635–1640CrossRef
20.
go back to reference Cakir A, Ozturan ŞG, Yildiz D, Erden B et al (2019) Evaluation of photoreceptor outer segment length in hydroxychloroquine users. Eye (Lond) 33:1321–1326CrossRef Cakir A, Ozturan ŞG, Yildiz D, Erden B et al (2019) Evaluation of photoreceptor outer segment length in hydroxychloroquine users. Eye (Lond) 33:1321–1326CrossRef
21.
go back to reference Allahdina AM, Chen KG, Alvarez JA, Wong WT, Chew EY, Cukras CA (2019) Longitudinal changes in eyes with hydroxychloroquine retinal toxicity. Retina 39:473–484CrossRef Allahdina AM, Chen KG, Alvarez JA, Wong WT, Chew EY, Cukras CA (2019) Longitudinal changes in eyes with hydroxychloroquine retinal toxicity. Retina 39:473–484CrossRef
22.
go back to reference Grassmann F, Bergholz R, Mandl J, Jagle H, Ruether K, Weber BH (2015) Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmol 25:18CrossRef Grassmann F, Bergholz R, Mandl J, Jagle H, Ruether K, Weber BH (2015) Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmol 25:18CrossRef
23.
go back to reference Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL (1978) Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 17:1158–1175PubMed Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL (1978) Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 17:1158–1175PubMed
24.
go back to reference Turgut B, Turkcuoglu P, Serdar Koca S, Aydemir O (2009) Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol 28:607–609CrossRef Turgut B, Turkcuoglu P, Serdar Koca S, Aydemir O (2009) Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol 28:607–609CrossRef
25.
go back to reference de Sisternes L, Hu J, Rubin DL, Marmor MF (2015) Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci 56:3415–3426CrossRef de Sisternes L, Hu J, Rubin DL, Marmor MF (2015) Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci 56:3415–3426CrossRef
26.
go back to reference Eo DR, Lee MG, Ham DI, Kang SW et al (2017) Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci 32:522–527CrossRef Eo DR, Lee MG, Ham DI, Kang SW et al (2017) Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci 32:522–527CrossRef
27.
go back to reference Hagag AM, Gao SS, Jia Y, Huang D (2017) Optical coherence tomography angiography: technical principles and clinical applications in ophthalmology. Taiwan J Ophthalmol 7:115–129CrossRef Hagag AM, Gao SS, Jia Y, Huang D (2017) Optical coherence tomography angiography: technical principles and clinical applications in ophthalmology. Taiwan J Ophthalmol 7:115–129CrossRef
Metadata
Title
Is optical coherence tomography angiography a useful tool in the screening of hydroxychloroquine retinopathy?
Authors
Hatice Nur Tarakcioglu
Abdullah Ozkaya
Ulviye Yigit
Publication date
01-01-2021
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 1/2021
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-020-01549-4

Other articles of this Issue 1/2021

International Ophthalmology 1/2021 Go to the issue